
## Niteesh K Choudhry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1301992/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Systematic Review: The Relationship between Clinical Experience and Quality of Health Care. Annals of Internal Medicine, 2005, 142, 260.	3.9	1,164
2	Treat or Eat: Food Insecurity, Cost-related Medication Underuse, and Unmet Needs. American Journal of Medicine, 2014, 127, 303-310.e3.	1.5	260
3	Measuring concurrent adherence to multiple related medications. American Journal of Managed Care, 2009, 15, 457-64.	1.1	224
4	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-naÃ <sup>-</sup> ve women. American Journal of Obstetrics and Gynecology, 2016, 215, 353.e1-353.e18.	1.3	220
5	Association of a Smartphone Application With Medication Adherence and Blood Pressure Control. JAMA Internal Medicine, 2018, 178, 802.	5.1	214
6	The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Archives of Internal Medicine, 2011, 171, 814-22.	3.8	172
7	Untangling the relationship between medication adherence and post–myocardial infarction outcomes. American Heart Journal, 2014, 167, 51-58.e5.	2.7	162
8	Effect of Reminder Devices on Medication Adherence. JAMA Internal Medicine, 2017, 177, 624.	5.1	160
9	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BEST LI) Trial. Journal of the American Heart Association, 2016, 5, .	3.7	158
10	Trends in adherence to secondary prevention medications in elderly postâ€myocardial infarction patients. Pharmacoepidemiology and Drug Safety, 2008, 17, 1189-1196.	1.9	121
11	At Pitney Bowes, Value-Based Insurance Design Cut Copayments And Increased Drug Adherence. Health Affairs, 2010, 29, 1995-2001.	5.2	102
12	Four-Dollar Generics — Increased Accessibility, Impaired Quality Assurance. New England Journal of Medicine, 2010, 363, 1885-1887.	27.0	83
13	Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiology and Drug Safety, 2015, 24, 1105-1113.	1.9	76
14	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: AÂCohort Study. American Journal of Medicine, 2015, 128, 653.e7-653.e16.	1.5	75
15	Assessing The Evidence For Value-Based Insurance Design. Health Affairs, 2010, 29, 1988-1994.	5.2	74
16	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	5.1	71
17	Barriers to Insulin Progression Among Patients With Type 2 Diabetes. The Diabetes Educator, 2013, 39, 53-65.	2.5	70
18	Effect of Medication Co-payment Vouchers on P2Y <sub>12</sub> Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 44.	7.4	67

#	Article	IF	CITATIONS
19	Initial Choice of Oral Glucose-Lowering Medication for Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 1955.	5.1	64
20	A systematic overview of systematic reviews evaluating medication adherence interventions. American Journal of Health-System Pharmacy, 2020, 77, 138-147.	1.0	63
21	Drug Company–Sponsored Patient Assistance Programs: A Viable Safety Net?. Health Affairs, 2009, 28, 827-834.	5.2	62
22	Targeting cardiovascular medication adherence interventions. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 381-397.	1.5	58
23	Observing versus Predicting: Initial Patterns of Filling Predict Longâ€Term Adherence More Accurately Than Highâ€Dimensional Modeling Techniques. Health Services Research, 2016, 51, 220-239.	2.0	57
24	Letters designed with behavioural science increase influenza vaccination in Medicare beneficiaries. Nature Human Behaviour, 2018, 2, 743-749.	12.0	56
25	Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. Annals of Internal Medicine, 2017, 166, 81.	3.9	45
26	Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels. JAMA Internal Medicine, 2014, 174, 1938.	5.1	41
27	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Affairs, 2018, 37, 125-133.	5.2	41
28	Rationale and design of the Medication adherence Improvement Support App For Engagement—Blood Pressure (MedISAFE-BP) trial. American Heart Journal, 2017, 186, 40-47.	2.7	38
29	Randomized, Controlled Trials in Health Insurance Systems. New England Journal of Medicine, 2017, 377, 957-964.	27.0	35
30	Comparative Costâ€Effectiveness of Interventions to Improve Medication Adherence after Myocardial Infarction. Health Services Research, 2012, 47, 2097-2117.	2.0	34
31	Limiting the Duration of Opioid Prescriptions. JAMA Internal Medicine, 2016, 176, 583.	5.1	34
32	Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis. American Journal of Medicine, 2018, 131, 795-804.e5.	1.5	31
33	Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiology and Drug Safety, 2018, 27, 495-503.	1.9	30
34	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004632.	2.2	30
35	Patients' Preferences in Anticoagulant Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 912-919.	2.2	28
36	Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: The ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial. PLoS ONE, 2019, 14, e0214754.	2.5	28

#	Article	IF	CITATIONS
37	The Impact of Text Messaging on Medication Adherence and Exercise Among Postmyocardial Infarction Patients: Randomized Controlled Pilot Trial. JMIR MHealth and UHealth, 2017, 5, e110.	3.7	28
38	Prevalence, effectiveness, and characteristics of pharmacy-based medication synchronization programs. American Journal of Managed Care, 2016, 22, 179-86.	1.1	28
39	Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. Pharmacoepidemiology and Drug Safety, 2015, 24, 647-653.	1.9	24
40	Long-Term Cost-Effectiveness of Providing Full Coverage for Preventive Medications After Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 252-259.	2.2	24
41	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. American Heart Journal, 2016, 180, 90-97.	2.7	24
42	Hypertension Management in Brazil: Usual Practice in Primary Care—A Meta-Analysis. International Journal of Hypertension, 2017, 2017, 1-9.	1.3	22
43	Medication adherence and healthcare disparities: impact of statin co-payment reduction. American Journal of Managed Care, 2015, 21, 696-704.	1.1	22
44	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. American Journal of Gastroenterology, 2014, 109, 1850-1855.	0.4	21
45	Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes. JAMA Network Open, 2019, 2, e190657.	5.9	19
46	Defining a Research Agenda for Layperson Prehospital Hemorrhage Control. JAMA Network Open, 2020, 3, e209393.	5.9	19
47	A Call for a Systems-Thinking Approach to Medication Adherence. JAMA Internal Medicine, 2018, 178, 950.	5.1	17
48	Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Trial on Prescribing Patterns: A Time-Series Analysis. Annals of Pharmacotherapy, 2008, 42, 1563-1572.	1.9	16
49	Patterns and predictors of physician adoption of new cardiovascular drugs. Healthcare, 2018, 6, 33-40.	1.3	16
50	The Promise and Pitfalls of Pragmatic Clinical Trials for Improving Health Care Quality. JAMA Network Open, 2018, 1, e183376.	5.9	16
51	Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients With Poorly Controlled Cardiometabolic Disease. American Journal of Cardiology, 2020, 125, 376-382.	1.6	16
52	Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine, 2012, 2, 158-174.	2.5	14
53	Cost-related medication underuse: Prevalence among hospitalized managed care patients. Journal of Hospital Medicine, 2012, 7, 104-109.	1.4	14
54	Text Messaging and Patient Engagement in an Increasingly Mobile World. Circulation, 2016, 133, 555-556.	1.6	14

#	Article	IF	CITATIONS
55	Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implementation Science, 2021, 16, 9.	6.9	14
56	Implementing randomized effectiveness trials in large insurance systems. Journal of Clinical Epidemiology, 2013, 66, S5-S11.	5.0	12
57	Using Implementation Science to Optimize the Uptake of Evidence-Based Medicine into Dermatology Practice. Journal of Investigative Dermatology, 2020, 140, 952-958.	0.7	12
58	Use of Data-Driven Methods to Predict Long-term Patterns of Health Care Spending for Medicare Patients. JAMA Network Open, 2020, 3, e2020291.	5.9	12
59	Rationale and design of the R andomized E valuation to M easure I mprovements in N on-adherence from Low-Cost D evices (REMIND) trial. Contemporary Clinical Trials, 2015, 43, 53-59.	1.8	11
60	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	2.7	11
61	Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial. BMJ Open, 2017, 7, e016551.	1.9	10
62	Leveraging Social Networks for the Assessment and Management of Neurological Patients. Seminars in Neurology, 2022, 42, 136-148.	1.4	9
63	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.1	8
64	Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes. JAMA Network Open, 2020, 3, e1919645.	5.9	8
65	Preferences for mHealth Technology and Text Messaging Communication in Patients With Type 2 Diabetes: Qualitative Interview Study. Journal of Medical Internet Research, 2021, 23, e25958.	4.3	8
66	Evidence-Based Prescribing and Polypharmacy for Patients With Heart Failure. Annals of Internal Medicine, 2021, 174, 1165-1166.	3.9	7
67	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. Hypertension Research, 2021, 44, 1471-1482.	2.7	7
68	Rationale and design of the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic trial. Contemporary Clinical Trials, 2017, 59, 57-63.	1.8	6
69	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient, 2019, 12, 235-246.	2.7	6
70	Recommendations for the Conduct and Reporting of Research Involving Flexible Electronic Health Record–Based Interventions. Annals of Internal Medicine, 2020, 172, S110-S115.	3.9	6
71	REinforcement learning to improve non-adherence for diabetes treatments by Optimising Response and Customising Engagement (REINFORCE): study protocol of a pragmatic randomised trial. BMJ Open, 2021, 11, e052091.	1.9	6
72	Not there yet: using data-driven methods to predict who becomes costly among low-cost patients with type 2 diabetes. BMC Endocrine Disorders, 2020, 20, 125.	2.2	5

#	Article	IF	CITATIONS
73	Virtual Team Rounding. Academic Medicine, 2021, Publish Ahead of Print, .	1.6	5
74	Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data. Health Services Research, 2021, , .	2.0	5
75	Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis. BMJ Open, 2016, 6, e010958.	1.9	4
76	Effect of Automated Immunization Registry-Based Telephonic Interventions on Adult Vaccination Rates in Community Pharmacies: A Randomized Controlled Trial. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 989-994.	0.9	3
77	The accuracy of self-reported blood pressure in the Medication adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) trial: Implications for pragmatic trials. American Heart Journal, 2020, 220, 68-72.	2.7	3
78	Prescribing decision making by medical residents on night shifts: A qualitative study. Medical Education, 2022, 56, 1032-1041.	2.1	3
79	Impact of Massachusetts Health Reform on Enrollment Length and Health Care Utilization in the Unsubsidized Individual Market. Health Services Research, 2017, 52, 1118-1137.	2.0	2
80	Overcoming Decisional Gaps in High-Risk Prescribing by Junior Physicians Using Simulation-Based Training: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e31464.	1.0	2
81	Design of the Spine Pain Intervention to Enhance Care Quality And Reduce Expenditure Trial (SPINE) Tj ETQq1 1 ( Contemporary Clinical Trials, 2021, 111, 106602.	0.784314 1.8	rgBT /Overloo 1
82	Randomised controlled trial targeting habit formation to improve medication adherence to daily oral medications in patients with gout. BMJ Open, 2021, 11, e055930.	1.9	1
83	Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. Annals of Internal Medicine, 2017, 166, 761.	3.9	0
84	A perspective on U.S. drug reimportation. Minnesota Medicine, 2005, 88, 46-51.	0.1	0
85	A novel modality for real-time measurement of provider happiness. JAMIA Open, 2022, 5, ooac009.	2.0	0